Stay updated on Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial

Sign up to get notified when there's something new on the Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    7 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:43:19.000Z thumbnail image
  6. Check
    14 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the toxicities and efficacies of afatinib and pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma in the ALPHA Study.
    Difference
    0.1%
    Check dated 2024-06-06T14:28:13.000Z thumbnail image
  7. Check
    29 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying the types of squamous cell carcinoma and other health conditions required for inclusion in the study. Previously, this section had no information provided.
    Difference
    50%
    Check dated 2024-05-22T21:02:42.000Z thumbnail image
  8. Check
    51 days ago
    Change Detected
    Difference
    1.0%
    Check dated 2024-04-30T22:23:32.000Z thumbnail image

Stay in the know with updates to Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial page.